Cargando…

Is It Possible to Discontinue Tumor Necrosis Factor Antagonists after Psoriasis Remission?

Tumor necrosis factor (TNF) antagonists are highly effective treatments for psoriasis. These agents provide the opportunity to improve disease activity and achieve clinical remission. Despite its efficacy, long-term use of biologics is associated with high financial costs and possibly life-threateni...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Byungsoo, Maverakis, Emanual, Raychaudhuri, Siba P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Dermatological Association; The Korean Society for Investigative Dermatology 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992562/ https://www.ncbi.nlm.nih.gov/pubmed/33911640 http://dx.doi.org/10.5021/ad.2019.31.5.495

Ejemplares similares

BIOLOGICAL THERAPY OF PSORIASIS
por: Sivamani, Raja K, et al.
Publicado: (2010)

Incidence, Clinical Features, Management, and Prevention of Herpes Zoster in Patients Receiving Antitumor Necrosis Factor Therapy: A Clinical Review
por: Kim, Byung-Soo, et al.
Publicado: (2020)

Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriasis
por: Gondo, George, et al.
Publicado: (2022)

Remission of Psoriasis and Psoriatic Arthritis During Bevacizumab Therapy for Renal Cell Cancer
por: Datta-Mitra, Ananaya, et al.
Publicado: (2014)

Dual mTOR Inhibition Is Required to Prevent TGF-β-Mediated Fibrosis: Implications for Scleroderma
por: Mitra, Anupam, et al.
Publicado: (2015)

Heterogeneity in Comparisons of Discontinuation of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis - A Meta-Analysis
por: Fisher, Anat, et al.
Publicado: (2016)

2D Visualization of the Psoriasis Transcriptome Fails to Support the Existence of Dual-Secreting IL-17A/IL-22 Th17 T Cells
por: Le, Stephanie T., et al.
Publicado: (2019)

Depression and Insomnia in Patients With Psoriasis and Psoriatic Arthritis Taking Tumor Necrosis Factor Antagonists
por: Wu, Chun-Ying, et al.
Publicado: (2016)

Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriatic Arthritis
por: Gondo, George, et al.
Publicado: (2022)

Correction: Heterogeneity in Comparisons of Discontinuation of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis—A Meta-Analysis
por: Fisher, Anat, et al.
Publicado: (2017)

Pathophysiology of Autoimmune Bullous Diseases: Nature Versus Nurture
por: Patel, Forum, et al.
Publicado: (2017)

Recent Update on Immunopathogenesis of Psoriasis
por: Chhabra, Seema, et al.
Publicado: (2022)

Use of tumor necrosis factor alpha (TNF α) antagonists in a patient with psoriasis and Chagas disease
por: Navarrete-Dechent, Cristián, et al.
Publicado: (2015)

SCID MOUSE MODEL OF PSORIASIS: A UNIQUE TOOL FOR DRUG DEVELOPMENT OF AUTOREACTIVE T-CELL AND TH-17 CELL-MEDIATED AUTOIMMUNE DISEASES
por: Raychaudhuri, Smriti K, et al.
Publicado: (2010)

Erythrodermic psoriasis after discontinuation of ixekizumab
por: Potter, Kathryn Anne, et al.
Publicado: (2017)

High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists
por: Guo, Angela, et al.
Publicado: (2022)

Prevalence and predictors of sustained remission/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review
por: Ward, Michael M., et al.
Publicado: (2023)

Prescriber preference for a particular tumour necrosis factor antagonist drug and treatment discontinuation: population-based cohort
por: Fisher, Anat, et al.
Publicado: (2014)

Long-term Remission of Atopic Dermatitis after Discontinuation of Dupilumab
por: MIYAMOTO, Shoko, et al.
Publicado: (2022)

Demyelinizing Neurological Disease after Treatment with Tumor Necrosis Factor-α Antagonists
por: Bruè, Claudia, et al.
Publicado: (2016)

Serum tumor necrosis factor alpha increased during remission with Etanercept
por: Spirchez, Mihaela, et al.
Publicado: (2011)

Serum Levels of Tumor Necrosis Factor - alpha in Patients With Psoriasis
por: Ovcina-Kurtovic, Nermina, et al.
Publicado: (2022)

Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial
por: Chaparro, María, et al.
Publicado: (2019)

Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study
por: Song, Joo Hye, et al.
Publicado: (2021)

Discontinuation of etanercept after clinical remission in patients with juvenile idiopathic arthritis
por: Cohen, Jean-David, et al.
Publicado: (2012)

Active postoperative acromegaly: sustained remission after discontinuation of somatostatin analogues
por: Alvarez-Escola, Cristina, et al.
Publicado: (2016)

Case series: Continued remission of PTSD symptoms after discontinuation of prazosin
por: Richardson, Christie, et al.
Publicado: (2023)

Nontuberculous Mycobacterium Infection and Tumor Necrosis Factor-α Antagonists
por: Swart, Reinout M., et al.
Publicado: (2009)

No impact of tumor necrosis-factor antagonists on the joint manifestations of sarcoidosis
por: Banse, Christopher, et al.
Publicado: (2013)

Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
por: Park, Jihye, et al.
Publicado: (2021)

Functional significance of nerve growth factor and its receptor (TrkA) in inflammatory arthritis
por: Raychaudhuri, Smriti K, et al.
Publicado: (2010)

Exploration of the recurrence in radiation brain necrosis after bevacizumab discontinuation
por: Zhuang, Hongqing, et al.
Publicado: (2016)

Effects of a Tumor Necrosis Factor-α Antagonist on Experimentally Induced Rhinosinusitis
por: Kim, Dong-Hyun, et al.
Publicado: (2011)

Remission of psoriasis during treatment with sorafenib
por: van Kester, Marloes S., et al.
Publicado: (2018)

Response to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid Arthritis
por: Bergman, Martin J., et al.
Publicado: (2014)

Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor α monoclonal antibody (Infliximab)
por: Lee, Jung Hoon, et al.
Publicado: (2007)

Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis
por: Karpes Matusevich, Aliza R, et al.
Publicado: (2021)

SUN-383 Sustained Clinical Improvement after Discontinuation of Mifepristone: Unexpected Remission of Hypercortisolism
por: Anderson, Robin, et al.
Publicado: (2019)

Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease
por: Gelbenegger, Georg, et al.
Publicado: (2022)

The incidence of psoriasis among smokers and/or former smokers inflammatory bowel diseases patients treated with tumor necrosis factor antagonist: A systematic review and meta-analysis
por: Yang, Meiqi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ka43hgofpojke75mflb9gs47aq